Has Jonathan Strober received payments from drug or device companies?

Yes. Drug and device makers reported $163,711 in general payments to Jonathan Strober across 194 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Strober did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Strober come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Strober

Pediatrics · San Francisco, CANPI 1457454308

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $100,172 of the $163,711 with a category attached, or 61.2%. Biogen accounts for 65.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $51,862, 2.1 times the $24,803 reported in 2019. Among pediatrics clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$163,711in general payments, 2019–2025

Across 194 payments — averaging $843.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$108K
Sarepta Therapeutics, Inc.$18K
Janssen Scientific Affairs, LLC$10K
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$7K
Pfizer$6K
Janssen Global Services, LLC$4K
plus $11K from 7 others

$312,591in research payments, 2019–2025

Across 81 payments — averaging $3859.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

PTC Therapeutics, Inc.$108K
Janssen Research & Development, LLC$69K
CSL Behring$40K
Genentech, Inc.$35K
AstraZeneca$35K
Mallinckrodt Enterprises LLC$26K

What the payments were for

Consulting fees$43,54027%
Speaking & faculty fees$100,17261%
Travel & lodging$14,4249%
Food & beverage$5,5763%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	113	$107,895
Sarepta Therapeutics, Inc.	21	$17,818
Janssen Scientific Affairs, LLC	13	$9,950
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	9	$7,291
Pfizer	3	$6,000
Janssen Global Services, LLC	16	$3,534
Johnson & Johnson	4	$3,494
AstraZeneca	3	$3,083
NS Pharma, Inc.	2	$1,327
Catalyst Pharmaceuticals, Inc.	2	$1,325
Argenx US, Inc.	2	$1,309
ITF Therapeutics LLC	4	$598
Astellas Pharma US Inc	2	$88

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SPINRAZA$68,080
Skyclarys$33,744
ZOLGENSMA$7,174
SOLIRIS$2,955
AGAMREE$1,325
VILTEPSO$1,313
VYVGART$1,309
ULTOMIRIS$128
QALSODY$127
Exondys 51$125
Elevidys$111

How this compares

$163,711 in reported general payments places this provider in the 95th percentile of 5,539 pediatrics providers in California.

See all pediatrics providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amondys-45Casimersen	13	$2,023,661
HizentraImmun Glob G(Igg)/Pro/Iga 0-50	18	$70,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Sarepta Therapeutics, Inc.Amondys-45	$17,818	$2,023,66113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,539 pediatrics providers in California.

Other pediatrics in San Francisco

Tonya ChaffeeSan Francisco$359K
Anthony PortaleSan Francisco$354K
David KesslerSan Francisco$335K
Anna MoscickiSan Francisco$88K
Philip RosenthalSan Francisco$82K
Yvette WildSan Francisco$75K
Ilona FriedenSan Francisco$62K
Farzana PerwadSan Francisco$30K
Melvin HeymanSan Francisco$25K
Mary LeshSan Francisco$21K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →